HOME

SLXP - Salix Pharmaceuticals Ltd

Read the Salix Pharmaceuticals Ltd company profile. See stock information, press releases, and the latest Tweets on Twitter. The Salix Pharmaceuticals Ltd is a company listed in New York NASDAQ.

Search into NYSE and TSX
by quote, company name or key word

facebooktwitterlinkedin
Mail

SLXP - Salix Pharmaceuticals Ltd

Salix Pharmaceuticals, Ltd. is a pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. As of December 31, 2010, the Company’s products include XIFAXAN, MOVIPREP, OSMOPREP, VISICOL, APRISO, METOZOLV, AZASAN, ANUSOL-HC, PROCTOCORT, PEPCID, Oral Susp","NYSE, Nasdaq, S&P, trading, US market, Asian market, Dow Jones, FTSE, DJIA, DAX, stocks, bonds, shares","Connect to the most current information on stocks and bonds on Reuters.com. What you need to know now about NYSE, Dow Jones, S&P, and Nasdaq at Reuters.com"

Salix Pharmaceuticals Ltd on Twitter


Abaxis Inc News


Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week ...
Fort Mills Times - May 17, 2013
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that presentations related to the investigation of two of the Company's products are scheduled to take place during Digestive Disease Week DDW®2013.

Salix Pharmaceuticals Ltd. Earnings Call Insights: Fulyzaq and Apriso
Wall St. Cheat Sheet - May 11, 2013
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) recently reported its first quarter earnings and discussed the following topics in its earnings conference call.
Salix Pharma Q1 Profit Rises - Quick Facts - NASDAQ.com - NASDAQ

Salix Pharmaceuticals to Present at BofA Merrill Lynch 2013 Health Care ...
DailyFinance - May 8, 2013
RALEIGH, N.C.--(BUSINESS WIRE)-- Salix Pharmaceuticals, Ltd. (NAS: SLXP) today announced that the Company will present at the BofA Merrill Lynch 2013 Health Care Conference in Las Vegas, NV on Tuesday, May 14 at 4:20 p.m.

SALIX PHARMACEUTICALS, LTD. : Salix Pharmaceuticals to Present at BofA ...
4-traders (press release) - May 7, 2013
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases.

SALIX PHARMACEUTICALS, LTD. : Salix Pharmaceuticals Announces 1Q2013 ...
4-traders (press release) - Apr 25, 2013
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report first quarter 2013 financial results following the close of the U.S.

Salix Pharmaceuticals Earnings Preview: Can This Streak Continue?
Wall St. Cheat Sheet - May 9, 2013
Salix Pharmaceuticals, Ltd. develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases.

Salix Pharmaceuticals PT Raised to $55.00 (SLXP)
Mideast Time - May 14, 2013
Salix Pharmaceuticals, Ltd. logo Salix Pharmaceuticals (NASDAQ: SLXP) had its target price raised by UBS AG from $54.00 to $55.00 in a research note issued to investors on Friday, StockRatingsNetwork reports.

Progenics Pharmaceuticals Added to the NASDAQ Biotechnology Index
NASDAQ - 17 hours ago
Progenics' first commercial product, Relistor® (methylnaltrexone bromide) for opioid-induced constipation, is marketed and in further development by Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd.

PROGENICS PHARMACEUTICALS, INC. : Progenics Pharmaceuticals to Host ...
4-traders (press release) - May 6, 2013
Progenics' first commercial product, Relistor® (methylnaltrexone bromide) for opioid-induced constipation, is marketed and in further development by Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd ...

Salix Beats on Earnings - Analyst Blog - NASDAQ.com
NASDAQ - May 14, 2013
Salix Pharmaceuticals, Ltd. ( SLXP ) posted first quarter earnings of 56 cents per share, above the Zacks Consensus Estimate of 55 cents and the year-ago earnings of 42 cents.



Next Company >>